6th Novel Generation Conjugates Summit

The 6th Novel Generation Conjugates Summit explores innovations in bioconjugation, targeted drug delivery, and novel therapeutic strategies for enhanced efficacy and precision in treatment.

Key Topics

• Targeted protein degraders as next-generation antibody payloads
• Advancing nucleotide-based therapeutics with antibody-oligonucleotide conjugates
• Overcoming tumor heterogeneity via multispecific targeting
• Discovery of precision antibody-drug conjugates with novel degrader payloads
• Bright Peak immunoconjugates as a new class of multifunctional biologics
• Optimizing bispecific ADCs for increased tumor specificity
• Bicycle conjugates for precision targeting of solid tumors
• Delivery of a BET protein degrader via a CEACAM6-targeted ADC
• Pioneering targeting ligands for groundbreaking conjugates
• Endosomal escape vehicle-conjugated morpholino oligomer therapeutics
• Design considerations for optimizing pharmacokinetic profiles
• Challenges in process development of antibody-radio conjugates
• Hormone-peptide conjugates as next-generation targeted therapy
• Leveraging peptide-drug conjugates for unlocking new oncology targets
• Pushing the envelope with bi-specific ADCs using novel glycobiotechnology
• Technology for degrader-antibody conjugates with mAb-like pharmacokinetics
• Highlighting cutting-edge discovery platforms for novel bioconjugates
• Revolutionizing bioconjugate synthesis and process development
• Targeted 225Ac therapy using small molecule, peptide, and antibody vectors
• Leveraging bispecific antibody-drug conjugates for high tumor selectivity

Who should Attend

• Oncology researchers
• Pharmaceutical scientists
• Bioconjugation specialists
• Medicinal chemists
• Biotech startup executives
• Regulatory affairs professionals
• Antibody-drug conjugate developers
• Translational medicine experts
• Clinical development professionals
• Immunotherapy researchers
• CMC and process development scientists
• Protein engineering specialists
• Academic researchers in targeted therapies
• Pharmacokinetics and drug metabolism scientists
• Radiopharmaceutical developers
• Biopharma investors and strategists
• Drug formulation and delivery experts
• Biomedical engineers
• Preclinical toxicologists
• Technology transfer and IP specialists